The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
CONCLUSIONS: Our data support the use of week 3 and EOT US for prediction of pCR in response-guided NAT and in planning of breast-conserving surgery. Change in tumor diameter on US as a continuous variable could be a valuable alternative to categorical RECIST 1.1 criteria.PMID:34166854 | DOI:10.1016/j.breast.2021.06.001 (Source: Breast)
Source: Breast - June 24, 2021 Category: Cancer & Oncology Authors: Monika Graeser Nadia Harbeck Oleg Gluz Rachel W ürstlein Christine Zu Eulenburg Claudia Schumacher Eva-Maria Grischke Helmut Forstbauer Moritz Dimpfl Michael Braun Matthias Christgen Hans Heinrich Kreipe Jochem Potenberg Raquel von Schumann Bahriye Aktas Source Type: research

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
Breast. 2021 Aug;58:170-172. doi: 10.1016/j.breast.2021.05.002. Epub 2021 May 7.NO ABSTRACTPMID:34158166 | DOI:10.1016/j.breast.2021.05.002 (Source: Breast)
Source: Breast - June 23, 2021 Category: Cancer & Oncology Authors: Maria-Joao Cardoso Kefah Mokbel Source Type: research

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
CONCLUSIONS: LRT in de novo metastatic breast cancer is not associated with improved OS. Results are consistent among different breast cancer subgroups. However, this conclusion should be interpreted with caution in view of the limitations identified in meta-analysis.PMID:34158167 | DOI:10.1016/j.breast.2021.05.003 (Source: Breast)
Source: Breast - June 23, 2021 Category: Cancer & Oncology Authors: Daniel Reinhorn Raz Mutai Rinat Yerushalmi Assaf Moore Eitan Amir Hadar Goldvaser Source Type: research

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
Breast. 2021 Aug;58:170-172. doi: 10.1016/j.breast.2021.05.002. Epub 2021 May 7.NO ABSTRACTPMID:34158166 | DOI:10.1016/j.breast.2021.05.002 (Source: Breast)
Source: Breast - June 23, 2021 Category: Cancer & Oncology Authors: Maria-Joao Cardoso Kefah Mokbel Source Type: research

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
CONCLUSIONS: LRT in de novo metastatic breast cancer is not associated with improved OS. Results are consistent among different breast cancer subgroups. However, this conclusion should be interpreted with caution in view of the limitations identified in meta-analysis.PMID:34158167 | DOI:10.1016/j.breast.2021.05.003 (Source: Breast)
Source: Breast - June 23, 2021 Category: Cancer & Oncology Authors: Daniel Reinhorn Raz Mutai Rinat Yerushalmi Assaf Moore Eitan Amir Hadar Goldvaser Source Type: research

Mammographic density and prognosis in primary breast cancer patients
CONCLUSIONS: Although MD is one of the strongest independent risk factors for BC, in our collective PMD is not associated with disease-free and overall survival in patients with BC.PMID:34157655 | DOI:10.1016/j.breast.2021.06.004 (Source: Breast)
Source: Breast - June 22, 2021 Category: Cancer & Oncology Authors: Felix Heindl Peter A Fasching Alexander Hein Carolin C Hack Katharina Heusinger Paul Gass Patrik P öschke Frederik A St übs R üdiger Schulz-Wendtland Arndt Hartmann Ramona Erber Matthias W Beckmann Julia Meyer Lothar H äberle Sebastian M Jud Julius Em Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
CONCLUSIONS: PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3-4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment.PMID:34130011 | DOI:10.1016/j.breast.2021.05.009 (Source: Breast)
Source: Breast - June 15, 2021 Category: Cancer & Oncology Authors: Xiao-Fei Chang Xiao-Lu Ren Jie-Quan Yang Jian-Jun Shi Jun-Heng Bai Meng-Sheng Cui Wen-Wen Dong Source Type: research

Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV
Breast. 2021 Jun 3;59:27-36. doi: 10.1016/j.breast.2021.05.014. Online ahead of print.ABSTRACTPURPOSE: Breast cancer outcomes in sub-Saharan Africa is reported to be poor, with an estimated five-year survival of 50% when compared to almost 90% in high-income countries. Although several studies have looked at the effect of HIV in breast cancer survival, the effect of ARTs has not been well elucidated.METHODS: All females newly diagnosed with invasive breast cancer from May 2015-September 2017 at Charlotte Maxeke Johannesburg Academic and Chris Hani Baragwanath Academic Hospital were enrolled. We analysed overall survival an...
Source: Breast - June 14, 2021 Category: Cancer & Oncology Authors: Boitumelo Phakathi Sarah Nietz Herbert Cubasch Caroline Dickens Therese Dix-Peek Maureen Joffe Alfred I Neugut Judith Jacobson Raquel Duarte Paul Ruff Source Type: research

Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy
CONCLUSIONS: IMNI was associated with improved DFS and OS in node-positive patients treated with mastectomy, post-mastectomy RT, and taxane-based chemotherapy, although the rate of locoregional recurrence was low.PMID:34126377 | DOI:10.1016/j.breast.2021.05.012 (Source: Breast)
Source: Breast - June 14, 2021 Category: Cancer & Oncology Authors: Won Kyung Cho Jee Suk Chang Seung Gyu Park Nalee Kim Doo Ho Choi Haeyoung Kim Yong Bae Kim Won Park Chang Ok Suh Source Type: research

Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV
Breast. 2021 Jun 3;59:27-36. doi: 10.1016/j.breast.2021.05.014. Online ahead of print.ABSTRACTPURPOSE: Breast cancer outcomes in sub-Saharan Africa is reported to be poor, with an estimated five-year survival of 50% when compared to almost 90% in high-income countries. Although several studies have looked at the effect of HIV in breast cancer survival, the effect of ARTs has not been well elucidated.METHODS: All females newly diagnosed with invasive breast cancer from May 2015-September 2017 at Charlotte Maxeke Johannesburg Academic and Chris Hani Baragwanath Academic Hospital were enrolled. We analysed overall survival an...
Source: Breast - June 14, 2021 Category: Cancer & Oncology Authors: Boitumelo Phakathi Sarah Nietz Herbert Cubasch Caroline Dickens Therese Dix-Peek Maureen Joffe Alfred I Neugut Judith Jacobson Raquel Duarte Paul Ruff Source Type: research

Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy
CONCLUSIONS: IMNI was associated with improved DFS and OS in node-positive patients treated with mastectomy, post-mastectomy RT, and taxane-based chemotherapy, although the rate of locoregional recurrence was low.PMID:34126377 | DOI:10.1016/j.breast.2021.05.012 (Source: Breast)
Source: Breast - June 14, 2021 Category: Cancer & Oncology Authors: Won Kyung Cho Jee Suk Chang Seung Gyu Park Nalee Kim Doo Ho Choi Haeyoung Kim Yong Bae Kim Won Park Chang Ok Suh Source Type: research

Population-based mammography screening attendance in Sweden 2017-2018: A cross-sectional register study to assess the impact of sociodemographic factors
The objective of this study was to examine the association between mammography screening attendance and sociodemographic factors in 15 of Sweden's 21 health care regions. Register-based information was collected on all mammography screening invitations and attendance during 2017 and 2018, and linked to individual-level sociodemographic data from Statistics Sweden. Odds ratios (ORs) and 95% confidence intervals (CIs) for attendance were computed by sociodemographic factor. The study sample included 1.5 million women, aged 40-75, with an overall screening attendance of 81.3%. The lowest odds of attending were found for women...
Source: Breast - June 12, 2021 Category: Cancer & Oncology Authors: Magdalena Lagerlund Anna Åkesson Sophia Zackrisson Source Type: research

Population-based mammography screening attendance in Sweden 2017-2018: A cross-sectional register study to assess the impact of sociodemographic factors
The objective of this study was to examine the association between mammography screening attendance and sociodemographic factors in 15 of Sweden's 21 health care regions. Register-based information was collected on all mammography screening invitations and attendance during 2017 and 2018, and linked to individual-level sociodemographic data from Statistics Sweden. Odds ratios (ORs) and 95% confidence intervals (CIs) for attendance were computed by sociodemographic factor. The study sample included 1.5 million women, aged 40-75, with an overall screening attendance of 81.3%. The lowest odds of attending were found for women...
Source: Breast - June 12, 2021 Category: Cancer & Oncology Authors: Magdalena Lagerlund Anna Åkesson Sophia Zackrisson Source Type: research

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
CONCLUSIONS: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses ≥1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians' knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes.PMID:34116366 | DOI:10.1016/j.breast.2021.05.013 (Source: Breast)
Source: Breast - June 11, 2021 Category: Cancer & Oncology Authors: Cynthia Villarreal-Garza Fernanda Mesa-Chavez Ana S Ferrigno Cynthia De la Garza-Ramos Alan Fonseca Karen Villanueva-Tamez Jose Y Campos-Salgado Marlid Cruz-Ramos David O Rodriguez-Gomez Sandy Ruiz-Cruz Paula Cabrera-Galeana Source Type: research

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22-86)] CAB had hazard ratio (HR) of 3 (1.83-5.21) and 2.5 (1.45-4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49-5.25), P = 0.0001); age [
Source: Breast - June 7, 2021 Category: Cancer & Oncology Authors: Dinesh Chandra Doval Anurag Mehta S P Somashekhar Aparna Gunda Gurpreet Singh Amanjit Bal Siddhant Khare Chandra Prakash V Serkad Manjula Adinarayan Naveen Krishnamoorthy Devanhalli Govinda Vijay Radha Anantakrishnan G S Bhattacharyya Manjiri M Bakre Source Type: research

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22-86)] CAB had hazard ratio (HR) of 3 (1.83-5.21) and 2.5 (1.45-4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49-5.25), P = 0.0001); age [
Source: Breast - June 7, 2021 Category: Cancer & Oncology Authors: Dinesh Chandra Doval Anurag Mehta S P Somashekhar Aparna Gunda Gurpreet Singh Amanjit Bal Siddhant Khare Chandra Prakash V Serkad Manjula Adinarayan Naveen Krishnamoorthy Devanhalli Govinda Vijay Radha Anantakrishnan G S Bhattacharyya Manjiri M Bakre Source Type: research

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22-86)] CAB had hazard ratio (HR) of 3 (1.83-5.21) and 2.5 (1.45-4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49-5.25), P = 0.0001); age [
Source: Breast - June 7, 2021 Category: Cancer & Oncology Authors: Dinesh Chandra Doval Anurag Mehta S P Somashekhar Aparna Gunda Gurpreet Singh Amanjit Bal Siddhant Khare Chandra Prakash V Serkad Manjula Adinarayan Naveen Krishnamoorthy Devanhalli Govinda Vijay Radha Anantakrishnan G S Bhattacharyya Manjiri M Bakre Source Type: research

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22-86)] CAB had hazard ratio (HR) of 3 (1.83-5.21) and 2.5 (1.45-4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49-5.25), P = 0.0001); age [
Source: Breast - June 7, 2021 Category: Cancer & Oncology Authors: Dinesh Chandra Doval Anurag Mehta S P Somashekhar Aparna Gunda Gurpreet Singh Amanjit Bal Siddhant Khare Chandra Prakash V Serkad Manjula Adinarayan Naveen Krishnamoorthy Devanhalli Govinda Vijay Radha Anantakrishnan G S Bhattacharyya Manjiri M Bakre Source Type: research

The role of CDK4/6 inhibitors in early breast cancer
Breast. 2021 May 25;58:160-169. doi: 10.1016/j.breast.2021.05.008. Online ahead of print.ABSTRACTThe use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of...
Source: Breast - June 4, 2021 Category: Cancer & Oncology Authors: Miguel Gil-Gil Emilio Alba Joaqu ín Gavilá Juan de la Haba-Rodr íguez Eva Ciruelos Pablo Tolosa Daniele Candini Antonio Llombart-Cussac Source Type: research

The role of CDK4/6 inhibitors in early breast cancer
Breast. 2021 May 25;58:160-169. doi: 10.1016/j.breast.2021.05.008. Online ahead of print.ABSTRACTThe use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of...
Source: Breast - June 4, 2021 Category: Cancer & Oncology Authors: Miguel Gil-Gil Emilio Alba Joaqu ín Gavilá Juan de la Haba-Rodr íguez Eva Ciruelos Pablo Tolosa Daniele Candini Antonio Llombart-Cussac Source Type: research

The role of CDK4/6 inhibitors in early breast cancer
Breast. 2021 May 25;58:160-169. doi: 10.1016/j.breast.2021.05.008. Online ahead of print.ABSTRACTThe use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of...
Source: Breast - June 4, 2021 Category: Cancer & Oncology Authors: Miguel Gil-Gil Emilio Alba Joaqu ín Gavilá Juan de la Haba-Rodr íguez Eva Ciruelos Pablo Tolosa Daniele Candini Antonio Llombart-Cussac Source Type: research

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
CONCLUSIONS: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support from healthcare providers leads to self-management strategies, which negatively affects adherence and persistence behaviour.PMID:34049260 | PMC:PMC8165559 | DOI:10.1016/j.breast.2021.05.005 (Source: Breast)
Source: Breast - May 28, 2021 Category: Cancer & Oncology Authors: Nicola Peddie Sommer Agnew Megan Crawford Diane Dixon Iain MacPherson Leanne Fleming Source Type: research

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
CONCLUSIONS: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support from healthcare providers leads to self-management strategies, which negatively affects adherence and persistence behaviour.PMID:34049260 | DOI:10.1016/j.breast.2021.05.005 (Source: Breast)
Source: Breast - May 28, 2021 Category: Cancer & Oncology Authors: Nicola Peddie Sommer Agnew Megan Crawford Diane Dixon Iain MacPherson Leanne Fleming Source Type: research

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
CONCLUSIONS: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support from healthcare providers leads to self-management strategies, which negatively affects adherence and persistence behaviour.PMID:34049260 | DOI:10.1016/j.breast.2021.05.005 (Source: Breast)
Source: Breast - May 28, 2021 Category: Cancer & Oncology Authors: Nicola Peddie Sommer Agnew Megan Crawford Diane Dixon Iain MacPherson Leanne Fleming Source Type: research

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
CONCLUSIONS: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support from healthcare providers leads to self-management strategies, which negatively affects adherence and persistence behaviour.PMID:34049260 | DOI:10.1016/j.breast.2021.05.005 (Source: Breast)
Source: Breast - May 28, 2021 Category: Cancer & Oncology Authors: Nicola Peddie Sommer Agnew Megan Crawford Diane Dixon Iain MacPherson Leanne Fleming Source Type: research

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
CONCLUSIONS: HT side effects significantly impact breast cancer survivor's quality of life. A lack of support from healthcare providers leads to self-management strategies, which negatively affects adherence and persistence behaviour.PMID:34049260 | DOI:10.1016/j.breast.2021.05.005 (Source: Breast)
Source: Breast - May 28, 2021 Category: Cancer & Oncology Authors: Nicola Peddie Sommer Agnew Megan Crawford Diane Dixon Iain MacPherson Leanne Fleming Source Type: research

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)
Breast. 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.ABSTRACTPURPOSE: To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa).METHODS: A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used ...
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Nat ália Araújo Milton Severo Luisa Lopes-Concei ção Filipa Fontes Teresa Dias Mariana Branco Samantha Morais V ítor Tedim Cruz Luis Ruano Susana Pereira Nuno Lunet Source Type: research

Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study
CONCLUSIONS: Supervised exercise increased the proportion of BC patients adhering to the PA guideline over time. Furthermore, MetS, body composition, HRQoL and symptoms improved. Our findings highlight the clinical relevance of supervised exercise during ET in overweight BC patients.CLINICAL TRIAL INFORMATION: (NCT02424292).PMID:34023558 | DOI:10.1016/j.breast.2021.05.004 (Source: Breast)
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Harm L Ormel Carolina P Schr öder Gabriela G F van der Schoot Nico-Derk L Westerink Annette W G van der Velden Boelo Poppema Aline H Vrieling Jourik A Gietema Annemiek M E Walenkamp Anna K L Reyners Source Type: research

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)
Breast. 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.ABSTRACTPURPOSE: To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa).METHODS: A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used ...
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Nat ália Araújo Milton Severo Luisa Lopes-Concei ção Filipa Fontes Teresa Dias Mariana Branco Samantha Morais V ítor Tedim Cruz Luis Ruano Susana Pereira Nuno Lunet Source Type: research

Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study
CONCLUSIONS: Supervised exercise increased the proportion of BC patients adhering to the PA guideline over time. Furthermore, MetS, body composition, HRQoL and symptoms improved. Our findings highlight the clinical relevance of supervised exercise during ET in overweight BC patients.CLINICAL TRIAL INFORMATION: (NCT02424292).PMID:34023558 | DOI:10.1016/j.breast.2021.05.004 (Source: Breast)
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Harm L Ormel Carolina P Schr öder Gabriela G F van der Schoot Nico-Derk L Westerink Annette W G van der Velden Boelo Poppema Aline H Vrieling Jourik A Gietema Annemiek M E Walenkamp Anna K L Reyners Source Type: research

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)
Breast. 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.ABSTRACTPURPOSE: To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa).METHODS: A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used ...
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Nat ália Araújo Milton Severo Luisa Lopes-Concei ção Filipa Fontes Teresa Dias Mariana Branco Samantha Morais V ítor Tedim Cruz Luis Ruano Susana Pereira Nuno Lunet Source Type: research

Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study
CONCLUSIONS: Supervised exercise increased the proportion of BC patients adhering to the PA guideline over time. Furthermore, MetS, body composition, HRQoL and symptoms improved. Our findings highlight the clinical relevance of supervised exercise during ET in overweight BC patients.CLINICAL TRIAL INFORMATION: (NCT02424292).PMID:34023558 | DOI:10.1016/j.breast.2021.05.004 (Source: Breast)
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Harm L Ormel Carolina P Schr öder Gabriela G F van der Schoot Nico-Derk L Westerink Annette W G van der Velden Boelo Poppema Aline H Vrieling Jourik A Gietema Annemiek M E Walenkamp Anna K L Reyners Source Type: research

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)
Breast. 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.ABSTRACTPURPOSE: To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa).METHODS: A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used ...
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Nat ália Araújo Milton Severo Luisa Lopes-Concei ção Filipa Fontes Teresa Dias Mariana Branco Samantha Morais V ítor Tedim Cruz Luis Ruano Susana Pereira Nuno Lunet Source Type: research

Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study
CONCLUSIONS: Supervised exercise increased the proportion of BC patients adhering to the PA guideline over time. Furthermore, MetS, body composition, HRQoL and symptoms improved. Our findings highlight the clinical relevance of supervised exercise during ET in overweight BC patients.CLINICAL TRIAL INFORMATION: (NCT02424292).PMID:34023558 | DOI:10.1016/j.breast.2021.05.004 (Source: Breast)
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Harm L Ormel Carolina P Schr öder Gabriela G F van der Schoot Nico-Derk L Westerink Annette W G van der Velden Boelo Poppema Aline H Vrieling Jourik A Gietema Annemiek M E Walenkamp Anna K L Reyners Source Type: research

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)
Breast. 2021 May 15;58:130-137. doi: 10.1016/j.breast.2021.05.006. Online ahead of print.ABSTRACTPURPOSE: To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa).METHODS: A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used ...
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Nat ália Araújo Milton Severo Luisa Lopes-Concei ção Filipa Fontes Teresa Dias Mariana Branco Samantha Morais V ítor Tedim Cruz Luis Ruano Susana Pereira Nuno Lunet Source Type: research

Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study
CONCLUSIONS: Supervised exercise increased the proportion of BC patients adhering to the PA guideline over time. Furthermore, MetS, body composition, HRQoL and symptoms improved. Our findings highlight the clinical relevance of supervised exercise during ET in overweight BC patients.CLINICAL TRIAL INFORMATION: (NCT02424292).PMID:34023558 | DOI:10.1016/j.breast.2021.05.004 (Source: Breast)
Source: Breast - May 23, 2021 Category: Cancer & Oncology Authors: Harm L Ormel Carolina P Schr öder Gabriela G F van der Schoot Nico-Derk L Westerink Annette W G van der Velden Boelo Poppema Aline H Vrieling Jourik A Gietema Annemiek M E Walenkamp Anna K L Reyners Source Type: research

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
Breast. 2021 May 12;58:113-120. doi: 10.1016/j.breast.2021.04.010. Online ahead of print.ABSTRACTINTRODUCTION: OncotypeDX© Recurrence Score (RS) is a multigene panel used to aid therapeutic decision making in early-stage, estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer.AIM: To compare responses to neoadjuvant endocrine therapy (NET) in patients with ER+/HER2-breast cancer following substratification by RS testing.METHODS: This systematic review was performed in accordance to the PRISMA guidelines. Studies evaluating pathological complete response (pCR), partial ...
Source: Breast - May 22, 2021 Category: Cancer & Oncology Authors: M G Davey É J Ryan M R Boland M K Barry A J Lowery M J Kerin Source Type: research

Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives
Breast. 2021 May 12;58:121-129. doi: 10.1016/j.breast.2021.04.011. Online ahead of print.ABSTRACTGenetic testing for hereditary breast and ovarian cancer following genetic counseling is based on guidelines that take into account particular features of the personal and family history, and clinical criteria conferring a probability of having a BRCA mutation greater than 10% as a threshold for accessing the test. However, besides reducing mortality and social impact, the extension of screening programs also for healthy family members would allow a huge saving of the rising costs associated with these pathologies, supporting t...
Source: Breast - May 22, 2021 Category: Cancer & Oncology Authors: Filomena Ficarazzi Manuela Vecchi Maurizio Ferrari Marco A Pierotti Source Type: research

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
Breast. 2021 May 12;58:113-120. doi: 10.1016/j.breast.2021.04.010. Online ahead of print.ABSTRACTINTRODUCTION: OncotypeDX© Recurrence Score (RS) is a multigene panel used to aid therapeutic decision making in early-stage, estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer.AIM: To compare responses to neoadjuvant endocrine therapy (NET) in patients with ER+/HER2-breast cancer following substratification by RS testing.METHODS: This systematic review was performed in accordance to the PRISMA guidelines. Studies evaluating pathological complete response (pCR), partial ...
Source: Breast - May 22, 2021 Category: Cancer & Oncology Authors: M G Davey É J Ryan M R Boland M K Barry A J Lowery M J Kerin Source Type: research

Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives
Breast. 2021 May 12;58:121-129. doi: 10.1016/j.breast.2021.04.011. Online ahead of print.ABSTRACTGenetic testing for hereditary breast and ovarian cancer following genetic counseling is based on guidelines that take into account particular features of the personal and family history, and clinical criteria conferring a probability of having a BRCA mutation greater than 10% as a threshold for accessing the test. However, besides reducing mortality and social impact, the extension of screening programs also for healthy family members would allow a huge saving of the rising costs associated with these pathologies, supporting t...
Source: Breast - May 22, 2021 Category: Cancer & Oncology Authors: Filomena Ficarazzi Manuela Vecchi Maurizio Ferrari Marco A Pierotti Source Type: research

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care.PMID:33992964 | DOI:10.1016/j.breast.2021.05.001 (Source: Breast)
Source: Breast - May 16, 2021 Category: Cancer & Oncology Authors: Benjamin Daniels Belinda E Kiely Monica Tang Nehmat Houssami Sarah J Lord Sallie-Anne Pearson Source Type: research

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care.PMID:33992964 | DOI:10.1016/j.breast.2021.05.001 (Source: Breast)
Source: Breast - May 16, 2021 Category: Cancer & Oncology Authors: Benjamin Daniels Belinda E Kiely Monica Tang Nehmat Houssami Sarah J Lord Sallie-Anne Pearson Source Type: research

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care.PMID:33992964 | DOI:10.1016/j.breast.2021.05.001 (Source: Breast)
Source: Breast - May 16, 2021 Category: Cancer & Oncology Authors: Benjamin Daniels Belinda E Kiely Monica Tang Nehmat Houssami Sarah J Lord Sallie-Anne Pearson Source Type: research

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care.PMID:33992964 | DOI:10.1016/j.breast.2021.05.001 (Source: Breast)
Source: Breast - May 16, 2021 Category: Cancer & Oncology Authors: Benjamin Daniels Belinda E Kiely Monica Tang Nehmat Houssami Sarah J Lord Sallie-Anne Pearson Source Type: research

Preoperative non-palpable breast lesion localization, innovative techniques and clinical outcomes in surgical practice: A systematic review and meta-analysis
The objective of the present meta-analysis was to determine the crude clinical outcomes reported for the NWNI techniques on BCS. A literature search was performed of PubMed, Embase and Scopus databases up to February 2021 in order to select all prospective or retrospective clinical trials on pre-operative breast lesion localization done with NWNI devices. All studies were assessed following the PRISMA recommendations. Continuous outcomes were described in averages corrected for sample size, while binomial outcomes were described using the weighted average proportion. Twenty-seven studies with a total of 2103 procedures wer...
Source: Breast - May 15, 2021 Category: Cancer & Oncology Authors: Francesco Garzotto Rosanna Irene Comoretto Silvia Michieletto Gianpaolo Franzoso Marcello Lo Mele Dario Gregori Maria Giuseppina Bonavina Fernando Bozza Francesca Caumo Tania Saibene Source Type: research